AbbVie's TRT Portfolio
AbbVie Inc. is a North Chicago–based pharmaceutical giant that spun off from Abbott Laboratories on January 1, 2013, with first-year revenues of $18.8 billion — driven almost entirely by immunology blockbuster Humira, not testosterone.1 In the testosterone space, AbbVie manufactures AndroGel, a topical gel that earned FDA approval on February 28, 2000, and held first-mover advantage in convenient transdermal TRT.2
The company is not a dominant TRT player. AndroGel represents a small fraction of AbbVie's portfolio, which centers on immunology, oncology, and neuroscience. Generic testosterone gels flooded the market after patent expiry around 2014–2015, eroding AndroGel's market share to single digits.3
This review focuses exclusively on AndroGel — the only AbbVie testosterone product. Expect clinical data from pivotal trials, real-world safety signals, and a blunt assessment of where a 25-year-old branded gel fits in today's TRT landscape.
- FDA Status: Approved February 28, 2000 (NDA 020438)
- Active Ingredient: Testosterone
- Formulation: Topical transdermal gel (1%, 1.62%)
- Strength Options: 12.5 mg, 25 mg, 50 mg packets; 20.25–81 mg pump actuation
- Administration: Topical application to shoulders, upper arms, or abdomen
- Frequency: Once daily
- Clinical Efficacy: 79–85% reach normal T range (300–1050 ng/dL) at steady-state
- Typical Cost: Branded $600–700 per 2-month supply; generics $50–200/month
- Manufacturer: AbbVie Inc., North Chicago, IL
- Generic Available: Yes (since ~2014–2015)
- Patent Status: Expired
- Competitors: Testim, Fortesta, Vogelxo, Perrigo/Upsher-Smith generics
How AndroGel Works
Active Ingredient & Formulations
AndroGel delivers bioidentical testosterone in 1% and 1.62% concentrations. Packet strengths range from 12.5 mg to 50 mg per dose; the pump dispenses 20.25–81 mg per actuation. Both formulations are alcohol-based gels designed for once-daily application.4
Transdermal Delivery
You apply the gel to shoulders, upper arms, or abdomen — never the scrotum or damaged skin. Testosterone absorbs through the epidermis into systemic circulation over 2–4 hours. Steady-state serum levels are reached within 14 days of daily use. Alcohol evaporates post-application, leaving testosterone embedded in the stratum corneum for gradual release.4
Clinical Evidence
Two 90-day Phase 3 trials enrolled 274 hypogonadal men. At steady-state, 79–85% of patients reached normal testosterone range (300–1050 ng/dL), with total testosterone increasing by 482 ng/dL over baseline and bioavailable testosterone rising by 390 ng/dL. Symptom improvements included better sexual function (measured by IIEF scores), mood, and energy.5
Dosing Protocols
Start at 50 mg daily (1% gel) or 40.5 mg daily (1.62% pump). Titrate based on serum testosterone levels at day 14 and day 28, typically adjusting by 25 mg increments. Maximum recommended dose: 100 mg daily for 1% gel, 81 mg daily for 1.62% pump.4
Apply at the same time each morning. Let the gel dry for 3–5 minutes before dressing. Wash hands immediately after application to prevent secondary exposure.
Duration of Effect
Steady-state testosterone levels occur within 14 days of consistent daily dosing. Peak serum concentrations appear 2–4 hours post-application, with levels declining gradually over 24 hours — hence the once-daily schedule.4
Miss a dose and your testosterone drops within 48 hours. Consistency matters more with topical gels than weekly injections.
Administration Method
Open the packet or pump the bottle. Squeeze the gel onto clean, dry, intact skin. Spread it in a thin layer across the application site — don't rub it in like lotion. Avoid showering or swimming for at least 2 hours to ensure full absorption.4
Cover the site with clothing once dry. Women and children should never touch unwashed application sites — secondary exposure can cause virilization in boys and hirsutism in women.
Bioidentical Testosterone is a synthetic hormone with the exact molecular structure as testosterone naturally produced by the body, ensuring compatibility with human hormone receptors and metabolism.
Transdermal Delivery is a method of administering medication through the skin, allowing the active ingredient to pass through the epidermis into the bloodstream without injection or oral ingestion.
Hypogonadal refers to a condition in which the testes produce insufficient testosterone, resulting in low serum testosterone levels and associated symptoms like reduced sexual function and fatigue.
Cost and Coverage
Branded AndroGel pricing is difficult to pin down in 2025 because virtually no one pays retail. The wholesale acquisition cost for a 75 g pump (roughly two months at 40.5 mg daily) runs $600–700, but that's the sticker price insurers and PBMs negotiate down.6
Generic testosterone gels changed the game after patents expired in 2014–2015. Perrigo, Upsher-Smith, and others flooded the market with bioequivalent 1% and 1.62% formulations priced at $50–200 per month — 70–90% cheaper than branded AndroGel.3 Most prescribers now default to generics unless a patient has a documented allergy to a specific inactive ingredient.
Insurance coverage is standard but requires prior authorization. Medicare Part D places testosterone gels in Tier 3 or 4, with copays ranging from $40 to $100 post-deductible. Commercial plans cover AndroGel in 80–90% of formularies, contingent on a diagnosis code for hypogonadism and two morning testosterone readings below 300 ng/dL.7
AbbVie offers the myAbbVie Assist program for uninsured or underinsured patients, providing free medication based on income eligibility. Commercially insured patients can access copay cards that cap out-of-pocket costs at $10–25 per month — though these savings don't apply if your insurer mandates generic substitution.8
Branded alternatives include Testim, Fortesta, and Vogelxo, all topical testosterone gels with similar pricing and efficacy. The competitive landscape is saturated. Unless you have a specific reason to avoid generics, the math favors generic testosterone 1% gel from any reputable manufacturer.
Pros and Cons
Pros
- Proven efficacy — 79–85% of patients reach normal testosterone range in Phase 3 trials5
- Convenient topical delivery — once-daily application, no needles, no injection site reactions
- Generic options available — cost savings of 70–90% compared to branded AndroGel3
- Long clinical history — FDA approved in 2000, extensive real-world safety data over 25 years2
- Mood and sexual function improvements documented in pivotal trials5
Cons
- Cardiovascular risk signals in observational data — some studies link Testosterone Gels to increased MI and stroke risk in older men9
- Generic market saturation — branded AndroGel offers no clinical advantage over $50/month generics
- Application site reactions — 17% of users report skin irritation, redness, or itching4
- Not ideal for patients preferring long-acting formulations — daily dosing requires adherence, unlike weekly injections or quarterly pellets
- Secondary exposure risk — women and children must avoid contact with application sites4
Best for:
Men who prefer topical delivery over injections, patients comfortable with once-daily application, cost-conscious users willing to choose generics, those with established TRT needs and stable dosing requirements.
Not ideal for:
Patients with sensitive skin or dermatologic conditions, men preferring long-acting formulations like pellets or weekly injections, households with young children or female partners who may come into contact with application sites, anyone prioritizing brand loyalty over cost savings.
Patient Experiences
No genuine user reviews, forum discussions, or patient sentiment data for AndroGel appeared in available research. Search results focus exclusively on AbbVie's corporate pipeline, stock performance, and legal actions — not patient-reported outcomes for testosterone products.10
This is a data gap, not a quality signal. AndroGel has been on the market for 25 years and millions of prescriptions have been filled. The absence of user sentiment in this analysis reflects source limitations, not product performance.
For real-world feedback, search Reddit communities like r/Testosterone and r/TRT, Drugs.com reviews, WebMD patient forums, and Facebook TRT support groups. Filter reviews by year — pre-2015 comments may reference branded AndroGel specifically, while post-2015 feedback often discusses generic equivalents.
Generic alternatives have broader user bases on review platforms, since most prescriptions now default to generics. Expect feedback themes around convenience (no needles), application hassles (messy, transfer risk), and efficacy variability (some users report better results with injections).
We'll update this section when comprehensive sentiment data becomes available. For now, clinical trial results remain the most reliable indicator of AndroGel's performance profile.